Piper Sandler analyst Jessica Tassan downgrades $Humana (HUM.US)$ to a hold rating, and adjusts the target price from $392 to $274.
According to TipRanks data, the analyst has a success rate of 45.4% and a total average return of -2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Humana (HUM.US)$'s main analysts recently are as follows:
For 2025, only a quarter of Humana's members are covered by bonus-qualified plans, a decrease from 94% in the previous year. The preliminary star results fell short of investors' expectations and present a substantial risk to the company's financial performance in 2026.
Despite a reduction in the outlook on Humana, the sentiment remains positive based on the company's proximity to the critical 4-Star threshold in several of its plans, which could be pivotal should their appeal succeed. Even in the case of an unsuccessful appeal, there's a belief in the company's potential to make a comeback in the following year. With management considering various mitigation strategies, it's acknowledged that there are numerous variables at play before definitive projections can be made. There's a degree of uncertainty regarding the company's ability to achieve its 3% margin goal by 2027.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派傑投資分析師Jessica Tassan下調$哈門那 (HUM.US)$至持有評級，並將目標價從392美元下調至274美元。
根據TipRanks數據顯示，該分析師近一年總勝率為45.4%，總平均回報率為-2.7%。
此外，綜合報道，$哈門那 (HUM.US)$近期主要分析師觀點如下：
到2025年，只有四分之一的Humana會員受到符合獎金條件的計劃的保障，低於去年的94％。初步的明星業績未達到投資者的預期，並對公司2026年的財務表現構成重大風險。
儘管Humana的前景有所下降，但由於該公司在幾項計劃中接近關鍵的四星門檻，市場情緒仍然樂觀，如果他們的上訴成功，這可能是至關重要的。即使上訴失敗，也有人相信該公司有可能在次年捲土重來。在管理層考慮各種緩解策略時，人們承認，在做出明確的預測之前，有許多變量在起作用。該公司到2027年實現3％的利潤率目標的能力存在一定程度的不確定性。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
